Akcea now shooting for $200M-plus as a new lineup of biotech IPOs prep for a launch
Akcea Therapeutics is upping the ante on its IPO.
The Ionis subsidiary originally mapped out a plan to raise $100 million in its initial offering …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
